`
`
`
`ACUITAS THERAPEUTICS, INC.,
`
`
`Plaintiff,
`
`UNITED STATES DISTRICT COURT
`SOUTHERN DISTRICT OF NEW YORK
`
`
`
`
`Case No. 22-cv-02229-ER
`
`
`
`
`v.
`
`
`
`
`
`
`
`
`GENEVANT SCIENCES GMBH AND
`ARBUTUS BIOPHARMA CORP.
`
`
`Defendants.
`
`
`
`
`
`RULE 7.1 CORPORATE DISCLOSURE STATEMENT
`
`Genevant Sciences GmbH (“Genevant”) submits the following statement of its corporate
`
`interests pursuant to Rule 7.1 of the Federal Rules of Civil Procedure.
`
`Genevant hereby states that its ultimate corporate parent is Roivant Sciences Ltd., a
`
`publicly-held company.
`
`
`
`Dated: April 15, 2022
`
`
`
`
`
`
`
`By: /s/ Isaac Nesser
`QUINN EMANUEL URQUHART & SULLIVAN
`Raymond Nimrod
`Matthew Robson
`Isaac Nesser
`51 Madison Avenue, 22nd Floor,
`New York, New York 10010
`raynimrod@quinnemanuel.com
`matthewrobson@quinnemanuel.com
`isaacnesser@quinnemanuel.com
`Telephone: (212) 849-7000
`Facsimile: (212) 849-7100
`
`Kevin P. B. Johnson
`555 Twin Dolphin Dr., 5th Floor
`Redwood Shores, CA 94065
`kevinjohnson@quinnemanuel.com
`Telephone: (650) 801-5000
`Facsimile: (650) 801-5100
`
`
`
`Case 1:22-cv-02229-MKV Document 21 Filed 04/15/22 Page 2 of 2
`
`
`Sandra Haberny, Ph.D.
`865 South Figueroa Street, 10th Floor
`Los Angeles, CA 90017
`sandrahaberny@quinnemanuel.com
`Telephone: (213) 443-3000
`Facsimile: (213) 443-3100
`
`Attorneys for Genevant Sciences GmbH
`
`
`
`
`
`